Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 104Multiple Myeloma 66Lymphoma 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Myelodysplastic Syndromes 51Lymphoma, Non-Hodgkin 51Leukemia 50Hodgkin Disease 42Lymphoma, Mantle-Cell 29Lymphoma, Large B-Cell, Diffuse 29Leukemia, Lymphocytic, Chronic, B-Cell 26Leukemia, Myelogenous, Chronic, BCR-ABL Positive 23Lymphoma, Follicular 22Burkitt Lymphoma 22Breast Neoplasms 22Recurrence 20Neoplasms, Plasma Cell 18Neuroblastoma 17Hematologic Neoplasms 17Lymphoma, B-Cell, Marginal Zone 15Myeloproliferative Disorders 14Lymphoma, Large-Cell, Immunoblastic 14Leukemia, Myelomonocytic, Chronic 12Leukemia, Biphenotypic, Acute 12Congenital Abnormalities 12Blast Crisis 10Anemia, Refractory, with Excess of Blasts 10Retinoblastoma 9Central Nervous System Neoplasms 9Sarcoma 8

Interventions

Paclitaxel 7Doxorubicin 5pembrolizumab 4pazopanib 4Gemcitabine 4Bevacizumab 4durvalumab 3Radiotherapy 3Propranolol 3Docetaxel 3regorafenib 2cemiplimab 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Nivolumab 2Ifosfamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trebananib 1trastuzumab duocarmazine 1talimogene laherparepvec 1talazoparib 1spartalizumab 1sintilimab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hemangiosarcoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT05799612 2026-02-13

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡